

November 11, 2016



*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. Pfizer to Close Two UK Plants

Pfizer has proposed closing two of its UK supply facilities following a review of its global supply network: the Hospira UK Ltd (Aseptic Services) Compounding site in North London and the Pfizer packaging and distribution site in Havant. Pfizer expects to exit the Hospira facility by May 2017 and the packaging and distribution site by the end of 2020. [Read More](#)

2. GSK to Close Australian Plant

GlaxoSmithKline Consumer Healthcare will close its manufacturing facility in Ermington, Australia, which makes OTC products, in a phased process over the next four years. The company said that the decision was made after an evaluation of the site showed that it would not be able to remain competitive in the long term. [Read More](#)

3. Valeant Evaluates Divestitures

Valeant Pharmaceuticals International said it is evaluating certain divestitures, including of Salix Pharmaceuticals, a Raleigh, North Carolina-headquartered specialty pharmaceutical company that Valeant acquired in 2014 for approximately \$15.8 billion. [Read More](#)

4. Mylan Submits Filing of Biosimilar Herceptin to FDA

Mylan has submitted a biologics license application to the FDA for a proposed biosimilar of Roche's anti-cancer drug, Herceptin (trastuzumab). Herceptin is one of Roche's top-selling drugs with 2015 global sales of CHF 6.54 billion (\$6.84 billion). [Read More](#)

5. ... And Starts Clinical Study of Biosimilar of BMS Arthritis Drug

Mylan and partner, Momenta Pharmaceuticals, a Cambridge, Massachusetts-based pharmaceutical company, have begun a Phase I study for a proposed biosimilar to Orencia (abatacept), Bristol-Myers Squibb's anti-arthritis drug. Orencia is a top-selling drug for BMS with 2015 worldwide sales of \$1.9 billion. The news is part of *DCAT Value Chain Insights Pipeline News* [Read More](#)

6. US PTO Denies Review of Formulation Patent for Biosimilar of AbbVie's Humira

A petition by Coherus BioSciences, a biosimilars developer, for an inter partes review of a formulation patent for AbbVie's Humira (adalimumab) has been denied by an appeals board of the US Patent and Trademark Office. Humira is AbbVie's top-selling drug with 2015 sales of \$14 billion. [Read More](#)

7. Astellas Forms Patient Experience Organization

Reflecting a trend for more patient-centric approaches, Astellas has created a new department, the Patient Experience Organization, in the Americas that will formally build on efforts to ensure that "the voice of the patient" is incorporated across all facets of the company. [Read More](#)

8. [Almac Invests \\$34 Million in Expansion](#)

Almac Group, a CDMO headquartered in Craigavon, Northern Ireland, plans to invest \$34 million to expand its operations in Europe and North America and to increase its global headcount to reach 5,000 by 2017. [Read More](#)

9. [UPS to Acquire Marken](#)

UPS, the shipping firm, has agreed to acquire Marken, a Research Triangle Park, North Carolina-based provider of logistics and supply-chain services for clinical trial materials. The move is part of UPS' strategy to build its life-sciences network by gaining more than 650 employees and 44 locations worldwide, including 10 depots, through the acquisition. [Read More](#)

10. [Recipharm Invests \\$1.3 Million in API Facility](#)

In the latest in a series of investments, Recipharm, a CDMO based in Jordbro, Sweden, has invested more than EUR 1.2 million (\$1.3 million) to enhance its small-scale GMP active pharmaceutical ingredient development and manufacturing capabilities in Paderno Dugnano, Italy. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Annum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org